Long-term Follow-up of the QuantiFERON TB-2G Test for Active Tuberculosis Disease
Long-term Follow-up of the QuantiFERON TB-2G Test for Active Tuberculosis Disease
复制标题
DOI：
10.2169/internalmedicine.47.1313
复制
发表时间：
2008-01-01
影响因子：
1.2
通讯作者：
Oka, Mikio
中科院分区：
文献类型：
--
作者：
Kobashi, Yoshihiro;Sugiu, Tadaaki;Oka, Mikio
目的 评估同一患者连续检测中 QuantiFERON TB-2G (QFT-2G) 检测结果的过渡性变化，并重新评估 QFT-2G 检测阳性反应作为结核感染治愈的最佳阈值。 方法 我们前瞻性地调查了 22 名活动性结核病 (TB) 患者开始抗结核药物治疗后三年内 QFT-2G 检测结果的过渡性变化。所有患者均进行抗结核药物治疗6个月。结果治疗完成后QFT-2G检测阳性率下降50%。此后，虽然治疗完成后6个月后QFT-2G检测结果的阳性率下降了45%，但两年后略有下降至41%，三年后下降至36%。如果截断值低于50%（三年后的IFN-水平/基线峰值的IFN-γ水平），则通过本研究，除开始抗结核治疗三年后的两例外，大多数病例都可以判断QFT-2G测试的转换。结论使用QFT-2G测试监测结核感染治愈中的标志物可能很困难。当 QFT-2G 测试用于监测活动性结核病对治疗的反应时，可能需要重新考虑 QFT-2G 测试阳性反应的截止水平。
Objective To evaluate transitional changes in QuantiFERON TB-2G (QFT-2G) test results in the serial testing on the same patients and to reevaluate the optimal threshold of positive response of QFT-2G test as a cure of TB infection.Methods We prospectively investigated transitional changes of QFT-2G test results in 22 patients with active tuberculosis (TB) over three years after the initiation of treatment with antituberculosis drugs. Treatment using antituberculosis drugs was performed for six months in all patients.Results The positive rate of QFT-2G test results decreased 50% at the treatment completion. Thereafter, although the positive rate of QFT-2G test results has been decreased 45% six months later even if treatment was finished, it decreased slightly to 41% two years later and 36% three years later. If the cut-off value was situated below 50% (IFN-level three years later/ IFN-gamma level of baseline peak value), we could judge the conversion of QFT-2G test in most cases except for two cases three years after the initiation of antituberculosis treatment through this study.Conclusion It may be difficult to monitor markers in the cure of TB infection using QFT-2G tests. The cutoff level for a positive response on QFT-2G test may need to be reconsidered when the test is used to monitor the response of active TB to therapy.